(Press-News.org) DOWNLOADABLE VIDEO
MIAMI, FLORIDA (EMBARGOED UNTIL MONDAY, DEC. 11, 2023, AT 2:45 P.M. ET) – Few standard treatments have been available for advanced myelofibrosis, a bone marrow disorder characterized by excessive scar tissue that disrupts the normal production of blood cells
But new research conducted by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating cancer centers indicates that a new type of targeted therapy may offer new treatment options – and hope – for these patients.
Their study results will be shared at ASH 2023, the American Society of Hematology’s annual meeting in San Diego, Dec. 9-12.
“It’s exciting to be part of this multicenter study because we’re seeing some encouraging results for a new type of targeted therapy for advanced myelofibrosis and other blood malignancies,” said Justin M. Watts, M.D., Sylvester hematologist who will be the study’s lead presenter at ASH. “Until now, there have been few standard treatments for these cancers.”
Watts and his collaborators are testing a targeted and orally bioavailable epigenetic inhibitor of Bromodomain and extra-terminal (BET) proteins, which regulate the expression of critical oncoproteins involved in the disease process underlying blood cancers such as myelofibrosis.
Their phase 1, dose-escalation/expansion study is looking at the BET inhibitor known as “INCB057643” as a monotherapy for patients with relapsed or refractory myelofibrosis or other advanced blood cancers, and in combination with the JAK inhibitor ruxolitinib for patients with advanced myelofibrosis who had poor results with ruxolitinib as a frontline drug.
Thus far, Watts noted, the results are encouraging. “These investigational agents are proving to be safe, well-tolerated and effective in treating a cluster of symptoms typically seen with myelofibrosis, including fatigue, bone pain, night sweats, enlarged spleen and anemia,” he said.
Surprisingly, he added, this BET inhibitor appears to treat anemia in some patients, unlike other drugs, including in patients who have failed previous treatment with a JAK inhibitor alone or as a combination therapy.
“That’s really exciting because anemia is often a major problem with these patients, and it usually gets worse, not better, with additional treatment,” he explained. “We’ve had patients who were needing biweekly transfusions become transfusion-independent while on this targeted therapy.”
An additional benefit, Watts said, is that it appears this therapy can be dosed at a level that does not produce the side effects seen with some other BET inhibitors, yet still produce the desired outcomes.
“It really has an unexpectantly good therapeutic window, especially when given in combination with the standard of care drug ruxolitinib,” he said. “We’re seeing good clinical results without the side effects.”
Next steps, he added, are to complete this phase I study in multiple, expanded cohorts for myelofibrosis and other malignancies, and to move to a randomized, phase 3 trial with this BET inhibitor added to ruxolitinib versus a placebo to determine if it improves survival rates among these patients.
“Epigenetic-targeted therapies really work for many of the patients we treat in our clinics, and in general have fewer side than chemotherapy,” Watts said. “And that’s both exciting and gratifying.”
Disclosures and funding information are available in the abstract.
Follow @SylvesterCancer on X to learn more about its research and care.
# # #
ASH Presentation Title:
“750. Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study”
Presentation Date/Time:
Monday, Dec. 11, 2023 at 2:45 p.m. ET (11:45 a.m. PT)
# # #
DOWNLOADABLE VIDEO
EMBARGOED UNTIL MONDAY, DEC. 11, 2023, AT 2:45 P.M. ET
END
Rotavirus causes gastroenteritis, a condition that includes diarrhea, deficient nutrient absorption and weight loss. Severe cases result in approximately 128,000 deaths annually in infants and children worldwide. Despite intense research on how rotavirus causes diarrhea, there is still no complete answer, but in this new study researchers at Baylor College of Medicine report a new mechanism by which rotavirus induces diarrhea, interfering with the normal absorption of nutrients in the intestine.
The study, published in Proceedings of the National Academy of Sciences, is the first to show that rotavirus-altered lipid metabolism in the intestine plays a ...
In a world-first, researchers from the GrapheneX-UTS Human-centric Artificial Intelligence Centre at the University of Technology Sydney (UTS) have developed a portable, non-invasive system that can decode silent thoughts and turn them into text.
The technology could aid communication for people who are unable to speak due to illness or injury, including stroke or paralysis. It could also enable seamless communication between humans and machines, such as the operation of a bionic arm or robot.
The ...
Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain
The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year. At the same time, the study shows that remaining on the drug not only promotes additional weight loss but preserves improvements in metabolic and cardiovascular health.
The results from the SURMOUNT-4 study, which appeared Dec. ...
DALLAS, Dec. 11, 2023 — The American Heart Association — the world’s leading voluntary organization dedicated to a world of longer, healthier lives for all — continues its commitment to address the lack of diversity, equity and inclusion in clinical trials for medical research with the selection of two early-career scientists for the inaugural Robert A. Winn Clinical Investigator Leadership Award in Cardiovascular Research (Winn CILA-CV). The award is sponsored by the Bristol Myers ...
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting. The combination was generally well-tolerated, a notable finding according to Craig A. Portell, MD, who presented the data for PrECOG, LLC, at the 65th American Society of Hematology (ASH) Meeting and Exposition in San Diego, California, ...
FOR IMMEDIATE RELEASE
December 11, 2023
ILSI Global press contact:
Katherine Broendel
+1 (202) 659-0074 Ext. 175
kbroendel@ilsi.org
WASHINGTON—The International Life Sciences Institute (ILSI) has announced that its Annual Meeting, Technologies and Climate Change: Shaking up 21st Century Food Systems – Promises and Pitfalls, will take place in Clearwater, Florida, 21-24 January 2024. ILSI's Annual Meeting will feature scientific presentations, professional development and networking opportunities for researchers, academics, industry leaders, nongovernmental organizations, as well as public sector and ...
Amanda Madden, Assistant Professor, History and Art History; Director, Geospatial History, received funding for the project: "La sfera (The Globe): A Late Medieval World of Merchants, Maps, & Manuscripts."
In collaboration with the project team, Co-PI Madden, Senior Developer Jason Heppler, and the Roy Rosenzweig Center for History and New Media (RRCHNM) propose to design and develop a digital edition of the text, including the user interface and data pipeline.
The NEH grant will fund the development of a dynamic, interactive ...
Scientists are developing an experiment to test whether gravity is quantum
In quantum mechanics, which describes the behaviour of atoms and molecules –objects behave differently to everything we know: they can be in a quantum superposition of being in two places at the same time
Now, scientists are investigating a way to determine whether gravity operates in this way, by levitating micro diamonds in a vacuum
If gravity is quantum, it will ‘entangle’ the diamonds – an intriguing phenomenon which strongly links two objects in ways impossible in everyday life
This research will help ...
BUFFALO, N.Y. – University at Buffalo research has identified how a misstep in the genesis of a key component of the kidney causes infantile cystinosis, a rare disease that significantly shortens the lifespan of patients. Published Nov. 30 in the International Journal of Molecular Sciences, the work reveals that the mechanisms that cause the disease could be addressed and potentially cured through the genome-editing technique CRISPR. That could make kidney transplants, the most effective treatment currently available for these patients, unnecessary.
Infantile ...
Raz Developing Advanced Model-Based Tools For Portfolio Management
Ali Raz, Professor, Systems Engineering and Operations Research (SEOR), received funding for the project: "Advanced Model-Based Tools for Portfolio Management and Analytic: System Architecture and Multi-Attribute Decision Making for Integrating Autonomy Phase 2 (AIRC RT-1081.07.5)."
Raz is supporting Purdue University and Georgia Tech Research Institute (GTRI) in the enhancement of the IAPR System-of-systems (SoS) tool suite.
Raz received $20,500 from Stevens Institute of Technology on a subaward from the U.S. Department of Defense for ...
